Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer

Phase 2 Recruiting 100 enrolled Peking Union Medical College Hospital

NaSingle-groupOpen-labelTreatment

After the standard first-line treatment, the treatment regimen was adjusted to a paclitaxel polymer micellar-based immunotherapy combination regimen

Evaluation	Drug	Modality	Dose	Route
Subject	Paclitaxel	Small molecule	100 mg/m2	Intravenous